Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP300649.RAGFZqMP_22By1Zw4L7KQGzmHWXM5FvutUZzg0Z_zzSrQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP300649.RAGFZqMP_22By1Zw4L7KQGzmHWXM5FvutUZzg0Z_zzSrQ130_assertion type Assertion NP300649.RAGFZqMP_22By1Zw4L7KQGzmHWXM5FvutUZzg0Z_zzSrQ130_head.
- NP300649.RAGFZqMP_22By1Zw4L7KQGzmHWXM5FvutUZzg0Z_zzSrQ130_assertion description "[Finally, our findings highlight that pharmacological inhibition of Cdk2 activity is a potential therapeutical principle for cancer therapy, in particular for tumors with activated Myc or Ras.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP300649.RAGFZqMP_22By1Zw4L7KQGzmHWXM5FvutUZzg0Z_zzSrQ130_provenance.
- NP300649.RAGFZqMP_22By1Zw4L7KQGzmHWXM5FvutUZzg0Z_zzSrQ130_assertion evidence source_evidence_literature NP300649.RAGFZqMP_22By1Zw4L7KQGzmHWXM5FvutUZzg0Z_zzSrQ130_provenance.
- NP300649.RAGFZqMP_22By1Zw4L7KQGzmHWXM5FvutUZzg0Z_zzSrQ130_assertion SIO_000772 19966300 NP300649.RAGFZqMP_22By1Zw4L7KQGzmHWXM5FvutUZzg0Z_zzSrQ130_provenance.
- NP300649.RAGFZqMP_22By1Zw4L7KQGzmHWXM5FvutUZzg0Z_zzSrQ130_assertion wasDerivedFrom befree-20150227 NP300649.RAGFZqMP_22By1Zw4L7KQGzmHWXM5FvutUZzg0Z_zzSrQ130_provenance.
- NP300649.RAGFZqMP_22By1Zw4L7KQGzmHWXM5FvutUZzg0Z_zzSrQ130_assertion wasGeneratedBy ECO_0000203 NP300649.RAGFZqMP_22By1Zw4L7KQGzmHWXM5FvutUZzg0Z_zzSrQ130_provenance.